logo

For the Inventor, By the Inventor

Dunlap, IL, United States of America

Cecil R Smith, Jr

USPTO Granted Patents = 8

Average Co-Inventor Count = 2.2

ph-index = 5

Forward Citations = 644(Granted Patents)


Company Filing History:

goldMedal8 out of 2,202 
 
The United States of America as Represented by the Secretary of
 patents

Years Active: 1976-1985

Loading Chart...
8 patents (USPTO):Explore Patents
1. 4532327 - Sesbanimide and the use thereof in treating leukemic tumors (1985-07-30),
2. 4418064 - Chemotherapeutically active maytansinoids: treflorine, trenudine, and (1983-11-29),
3. 4315929 - Method of controlling the European corn borer with trewiasine (1982-02-16),
4. 4313946 - Chemotherapeutically active maytansinoids from Trewia nudiflora (1982-02-02),
5. 4206221 - Cephalomannine and its use in treating leukemic tumors (1980-06-03),
6. 4203996 - Synthetic cephalotaxine esters having antileukemic P388 activity (1980-05-20),
7. 4152333 - Synthetic cephalotaxine esters having antileukemic activity (1979-05-01),
8. 3959312 - Synthesis of antitumor alkaloid deoxyharringtonine and its precursor (1976-05-25),

Title: The Innovative Contributions of Cecil R. Smith, Jr.

Introduction

Cecil R. Smith, Jr. is a notable inventor based in Dunlap, IL (US), recognized for his significant contributions to the field of medicinal chemistry. With a total of eight patents to his name, Smith has made remarkable strides in developing novel compounds that have potential therapeutic applications.

Latest Patents

Among his latest patents is the invention of sesbanimide, a novel alkaloid compound isolated from the leguminous plant Sesbania drummondii. This compound is characterized by its structural formula and has shown effectiveness as an antineoplastic agent in animal studies. Another significant patent involves a group of chemotherapeutically active maytansinoids, including treflorine and trenudine, discovered in the seed tissue of Trewia nudiflora. These compounds are uniquely characterized by a 12-membered ring and a distinguishing methoxy group, demonstrating efficacy in causing remission of various malignancies.

Career Highlights

Cecil R. Smith, Jr. has dedicated his career to advancing the field of cancer treatment through innovative research and development. His work has not only contributed to the scientific community but has also paved the way for potential new therapies that could benefit patients suffering from malignancies.

Collaborations

Throughout his career, Smith has collaborated with esteemed colleagues, including Richard G. Powell and Kenneth L

This text is generated by artificial intelligence and may not be accurate.
Please report any incorrect information to support@idiyas.com
Loading…